GSK leads the battle against infectious diseases in the vaccine battle to protect human health

1.

Compared to "curing the disease", "preventing the disease before it happens" is actually a better choice

Whether it is the immunization program implemented since the birth of a child, or the HPV vaccine for women in recent years and the shingles vaccine for middle-aged and elderly people, they are committed to the continuous upgrade and breakthrough of medical biotechnology to minimize people from suffering from diseases.

But in fact, the vaccination campaign for adults has not received equal attention to its importance and necessity

A set of data from a sample of 12,411 adults from Tencent Health Research shows that only 22% believe that women need to be vaccinated; only 30% agree that the earlier the vaccine is vaccinated, the sooner they will benefit; 27% do not Know where the vaccine should be given; 42%, 53%, and 63% of people do not know that cervical cancer, pneumonia, and shingles can be prevented by vaccines

Behind these data revealed the lack of adult awareness of vaccines

Feng Bixia, vice president of GlaxoSmithKline (hereinafter referred to as "GSK") and head of China's vaccine business, repeatedly emphasized the importance of GSK's vaccine business in an interview with the media, hoping to increase public awareness of diseases through continuous efforts and cooperation with all parties.

In China, GSK has never changed its original aspiration to "base on China, join hands with China, and serve China"

The three vaccines currently marketed by GSK in China are: it has won the Galen Award three times, known as the "Nobel Prize in the Medical Field", and is currently the only recombinant shingles that has been marketed in China for adults aged 50 and above.

In this promotion of adult vaccines and value awareness, GSK has never been absent and has been promoting it all the time

Vaccination is regarded by the WHO as the "most worthwhile investment", the most efficient and effective way to control the cost of the healthcare system

From 2019 to 2021, GSK supported the "2019-2030 Healthy China Action"-a public welfare project for youth health education, under the guidance of the National Health Commission, the National Bureau of Disease Control and Prevention, and sponsored by the China Health Promotion Foundation (CHPF), which was carried out nationwide Knowledge update and education activities on the theme of disease prevention and control for vaccinators and school doctors promote the prevention and treatment of cervical cancer

2.

Every time a sudden infectious disease challenge strikes, the value of vaccines will be further amplified

The difficulties can be seen in the history of herpes zoster vaccine, HPV vaccine, and hepatitis B vaccine, known as the "Three Musketeers" of adult vaccines, in China:

Among them, the shingles vaccine was included in the country's first batch of 48 urgently needed new drugs for priority review and approval in 2018, and was approved by the China National Medical Products Administration for the prevention of shingles in adults aged 50 and over in 2019
.
Feng Bixia was very emotional about this, “The shingles vaccine market was developed by GSK from scratch
.
For a long time, the knowledge of Chinese middle-aged and elderly people on shingles disease and vaccines has always been weak.
Yes, and once contracted with shingles, the pain caused by this disease can be described as'torment'.
Many patients describe it as more painful than childbirth
.
"

"The promotion of adult vaccines is imperative.
The value of vaccines is not only in the long-term protection of the body, away from illness, but also in saving potential medical expenses.
This is of great significance to individuals, families and society
.
"Feng Bixia said
.

In November 2021, an article published by the authoritative medical journal "The Lancet" confirmed that the HPV vaccine Cervix was used in the British immunization program to effectively prevent the occurrence of cervical cancer and precancerous lesions.
This is the first effective prevention by Cervix The direct evidence of cervical cancer prevention.
The study found that the incidence of cervical cancer and CIN3 decreased by 87% and 97%, respectively, compared with the non-vaccinated group in girls aged 12-13 years who were vaccinated with Cerex.
After being included in the immunization program, it has helped almost eliminate cervical cancer in women born since September 1, 1995
.

GSK's hepatitis B vaccine was launched globally in 1986.
It is the only imported hepatitis B vaccine with 35 years of global experience in China.
It is registered as a single vaccine in 122 countries and regions around the world
.
Since its launch, more than one billion doses have been used cumulatively
.

3.
Vaccine companies are in action

In the past two years, the COVID-19 pandemic that has raged around the world has renewed attention to the public health issue of “A bird’s good bow”.
At many vaccine-related industry seminars, people from government agencies, academia, and industry expressed their emotions.
The epidemic has given vaccine companies an opportunity to show their strength
.

As one of the world's largest vaccine suppliers, GSK has fully supported the fight against the epidemic since the outbreak of COVID-19 and announced a number of cooperation
.
In September 2020, "Fortune" magazine announced the sixth annual "Change the World" list.
GSK and other industry peers joined in the fight against the new crown epidemic and tied for the first place on the list
.

The vaccine production process is very complicated.
It is not only to determine the vaccine technical route, but also to ensure the combination and quality of the vaccine components to achieve the best immune response effect
.

Generally speaking, there are antigens in vaccines.
Compared with antigen vaccines alone, the use of adjuvant systems composed of different adjuvants in some vaccines can enhance the immune response of the vaccine, especially for the elderly and specific populations such as immunocompromised , The adjuvant system can also improve the quality of their immune response
.
The challenge of adjuvant research is to find the perfect match of adjuvants to provide effective and safe formulations
.
As a leader in the development of innovative vaccines using different adjuvant systems, GSK has developed several very representative and differentiated vaccine products
.

In the case of a pandemic, the use of adjuvants is particularly important.
It can reduce the amount of antigen required for each dose of vaccine, so that more doses of vaccine can be produced to provide more people, which is important for improving the global vaccine supply.
Significance
.

Since the outbreak of the new crown epidemic, relying on its advantages in science, technology, investment portfolio and resources, GSK has successively announced cooperation with enterprises and institutions such as the Epidemic Prevention Innovation Alliance (CEPI), Sanofi, Medicago, SK Bioscience, CureVac, etc.
Jointly promote the global research and development of candidate vaccines and new drugs, and are committed to promoting and ensuring the availability of the new crown vaccine to the greatest extent
.

Recently, GSK and Medicago, a biopharmaceutical company headquartered in Quebec City, announced that the plant-derived vaccine candidate for the 2019-nCoV with GSK pandemic adjuvant has achieved efficacy and safety in the global phase 3 placebo-controlled efficacy study.
Positive results
.

According to the results of the study, for any severity of new coronary pneumonia caused by the global Delta variant strain, its efficacy is 75.
3%, and the candidate vaccine is well tolerated.
There are no related serious adverse events reported in the vaccine group.
The final registration application materials will be submitted to Health Canada soon
.

In the future, the combination of GSK's existing pandemic adjuvants and Medicago's plant vaccine technology is extremely expected to become an effective vaccine choice that can remain stable under refrigerated conditions and help people cope with this global pandemic
.

4.
Go hand in hand with global partners

To deal with this huge pandemic, far from being able to be accomplished by a single company, it requires companies in all links and different roles to work hand in hand
.

Since the outbreak of the 2019 new crown epidemic, GSK responded immediately and fully supported the fight against the epidemic, and announced a number of cooperation, including the cooperation with industry partners to develop the second-generation mRNA new crown candidate vaccine, making it possible to respond to the 2019 coronavirus mutant strain; A statement of intent was reached with the "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX), committed to ensuring the fair distribution of effective new coronavirus vaccines internationally
.

In addition to providing adjuvants, GSK is also exploring the feasibility of vaccine technology strategies
.
The recent focus is to rapidly advance the joint development of the second-generation new crown vaccine with CureVac, and use the optimized second-generation mRNA platform to further apply it to provide new vaccines against other pathogens
.

The challenge posed by the new crown variant strain continues, and the third vaccination plan has just been rolled out.
There is still a great opportunity in the global vaccine market, but how to ensure accessibility and fairness is a problem
.

GSK has always been committed to enabling the new crown vaccine to be delivered to people who need it to ensure fair access to new crown vaccines and treatments around the world.
For example, adjuvants are provided fairly, some R&D projects are included in COVAX, and the CEO signs a list of commitments
.

Looking at the world, GSK currently has 20 vaccines to protect the health of the entire population and the entire life cycle
.
As the spectrum of diseases changes, GSK continues to explore more possibilities in the field of vaccines and is always at the forefront of science
.
As of July 2021, GSK has 19 candidate vaccines under development, covering multiple areas such as respiratory syncytial virus infection, meningitis, tuberculosis, malaria, hepatitis B treatment, new coronavirus infection, and Clostridium difficile infection
.
The successive launch of these products will contribute to global infectious disease control
.